Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

 
• By Ian Haydock, Brian Yang, and Joseph Haas

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

In February 6, 2018 the city of Beijing international high China scenery - Image
BeiGene is headquartered in the Chinese capital of Beijing

More from Deals

More from Business